Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer

Overview of attention for article published in Frontiers in Pharmacology, January 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (72nd percentile)
High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

twitter: 9 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 3 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 98,618 followers.

RT @cpa61: Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advance…

27 Nov 2023

Reply Repost Favourite

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer https://t.co/tINY8YTMn0 https://t.co/qJqPsQbmOh

02 Oct 2023

Reply Repost Favourite

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer https://t.co/jRLHEEsYTv https://t.co/RqiWmbmcVi

25 Aug 2023

Reply Repost Favourite

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer https://t.co/SsNHVZh7XT https://t.co/v0GUezWAJ4

18 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.